Artwork

内容由Pharma Manufacturing提供。所有播客内容(包括剧集、图形和播客描述)均由 Pharma Manufacturing 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Amneal's Parkinson's pill approved, Novo Nordisk withdraws Wegovy approval expansion bid, FDA delays BeiGene Tevimbra decision [The good, the bad, the ugly]

2:59
 
分享
 

Manage episode 433875456 series 2941835
内容由Pharma Manufacturing提供。所有播客内容(包括剧集、图形和播客描述)均由 Pharma Manufacturing 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly.

Up this week:

The good — Amneal gets FDA nod for Parkinson’s pill

The bad — Novo Nordisk withdraws bid for Wegovy label expansion in heart failure

The ugly — FDA delays decision on BeiGene Tevimbra as a first-line therapy

  continue reading

67集单集

Artwork
icon分享
 
Manage episode 433875456 series 2941835
内容由Pharma Manufacturing提供。所有播客内容(包括剧集、图形和播客描述)均由 Pharma Manufacturing 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly.

Up this week:

The good — Amneal gets FDA nod for Parkinson’s pill

The bad — Novo Nordisk withdraws bid for Wegovy label expansion in heart failure

The ugly — FDA delays decision on BeiGene Tevimbra as a first-line therapy

  continue reading

67集单集

Усі епізоди

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南